Public Policy
10/31/2012
The U.S. House of Representatives Energy and Commerce Committee has initiated an expanded investigation into the recent fungal meningitis outbreak. Specifically, the Committee is looking into whether remedial measures were taken after a 2004 inspection of the New England Compounding Center by the U.S. Food and Drug Administration (FDA) and the Massachusetts Board of Registration in Pharmacy and a 2006 warning letter from the FDA which documented significant violations. In addition, the U.S. Senate Committee on Health, Education, Labor and Pensions has requested that the New England Compounding Center, the Massachusetts Board of Pharmacy, and The U.S. Food and Drug Administration provide records that will assist the Committee in its investigation into the outbreak.
